5. 1998 : 4 companies (110 employees) 2006 : 62 companies ( 730 employees ) 160 Million € raised among VC’s 22 products in RPC & clinical trials 25 companies have total sales of 58 M€ GE : OUR ACHIEVEMENTS
6. 53% Biopharm a: 6% Bioinformatics Informatics 2% Chemistry 9% Others Sequencing – 1,9% Therapeutic screening – 3,7% Drug delivery – 7,4% Diagnostics – 14,8% Therapeutic research – 25,9% From Idea to Market acceptance Cancer Infectious (HIV - HepC) Ophthalmology Metabolics disorders Autoimmune Others PII-b – PII-III Orphan drug GE : GENOPOLE COMPANIES 17% Material Device 13% Agri Biotech Environment
7. GE : OUR OBJECTIVES 2010 100 companies ( 2 500 employees ) 5 to 10 success stories (IPOs, M&A, Sales) Products on the market Attract Big Pharma companies
8.
9. A Comprehensive set of facilities (80 000 m²) ranging from: - A simple office for the creator (20 to 50 m²) - A specific biotech ‘greenhouse’ (50 to 400 m²) - Larger facilities (500 to 2000+ m² ) OUR RESOURCES
10. OPERATIONALS FIELDS Crete meeting on Incubation Creation of value Duration Traditional incubation / 24 months From First day to First Round
11. Duration Interaction with Tech Transfer Office Grants POC/Market Think about « scale-up » Creation of value OPERATIONALS FIELDS
12. Duration Creation of value - Access to specific skills and expertise : - Business Development - Clinical Development - Regulatory Affairs - Scale-up OPERATIONALS FIELDS
![Where are we ? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],30 Km Paris Region Bio-cluster Top 1 in EU for S&T - 7,5 % GDP devoted to R&D -](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)